Melanoma Reagents | abinScience

Home > Featured Products > Oncology Research > Melanoma

Melanoma has become the paradigm for immune checkpoint therapy, with BRAF/MEK-targeted and PD-1/CTLA-4-based combination regimens transforming patient outcomes. abinScience provides antibodies, recombinant proteins, and assay kits spanning BRAF, MAPK pathway, melanocyte-lineage diagnostic markers (S100, gp100/PMEL, Melan-A), and the full spectrum of immune checkpoint targets. RUO

Key Biomarkers & Targets

BRAF

V600E/V600K

BRAF V600 mutations present in ~50% of cutaneous melanomas. Target of vemurafenib and dabrafenib. 79 antibodies for mutation-associated signaling studies.

Antibodies

PD-1 / PD-L1

CD279 / CD274

First cancer type where anti-PD-1 (nivolumab, pembrolizumab) achieved durable responses. 260+ combined antibodies, proteins, and biosimilars.

Antibodies • Proteins • Biosimilars

CTLA-4

CD152

Ipilimumab (anti-CTLA-4) was the first checkpoint inhibitor approved in melanoma. 144 products for combination immunotherapy studies.

Antibodies • Proteins • Biosimilars

LAG-3 / TIGIT / TIM-3

Next-Gen Checkpoints

Emerging immune checkpoints under active clinical investigation in melanoma (relatlimab + nivolumab). 125+ combined products.

Antibodies • Proteins • Biosimilars

gp100 / PMEL

Melanocyte Antigen

Melanoma-associated antigen; target of tebentafusp (bispecific gp100×CD3). 20 antibodies for tumor antigen detection and T-cell assay development.

Antibodies • Biosimilars

S100

S100B / S100A4

Classic IHC diagnostic marker for melanocytic lesions. Serum S100B used for monitoring metastatic disease progression. 41 products.

Antibodies • Proteins

Why Researchers Choose abinScience for Melanoma

MAPK Pathway Depth BRAF → MEK → ERK signaling cascade covered end-to-end. Antibodies for studying resistance mechanisms to BRAF/MEK inhibitor combinations.

Complete Checkpoint Portfolio PD-1, PD-L1, CTLA-4, LAG-3, TIGIT, TIM-3, IDO1 — the most comprehensive immune checkpoint reagent set for melanoma immuno-oncology research.

Melanocyte-Lineage Diagnostics S100, gp100/PMEL, Melan-A/MART-1, MITF, SOX10, tyrosinase — a full panel for melanoma diagnosis and differentiation from other malignancies.

Bispecific & TCR-T Reference gp100–peptide/HLA-A2 complex antibodies and tebentafusp biosimilar for next-generation bispecific and TCR-based therapy development.

Original Manufacturer Pricing Direct-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

BRAF/MEK resistance profiling: Use BRAF, MEK1/2, and phospho-ERK antibodies (WB, IHC) to characterize acquired resistance mechanisms in melanoma cell lines and PDX models.
Immune checkpoint combination screening: Evaluate PD-1 + CTLA-4, PD-1 + LAG-3, and other dual-blockade strategies with recombinant checkpoint proteins in reporter cell-based assays.
Melanoma vs. non-melanoma differential diagnosis: Apply our S100, SOX10, gp100, and Melan-A antibodies in IHC panels to distinguish melanoma from poorly differentiated carcinoma and other spindle-cell tumors.
Neoantigen & TCR-T development: Use our gp100/HLA-A2 complex reagents and IDO1 proteins for T-cell activation assays, antigen-specific killing, and tumor immune evasion studies.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Do you carry BRAF V600E mutation-specific antibodies?

Our anti-BRAF antibodies detect total BRAF protein. For V600E-specific detection, we recommend combining our BRAF antibodies (WB) with mutation-specific recombinant proteins as positive controls in your assay.

Which checkpoint antibodies are best for melanoma TIL analysis?

For tumor-infiltrating lymphocyte characterization, we recommend our anti-PD-1, CTLA-4, LAG-3, TIGIT, and TIM-3 antibodies. These are available as unconjugated or can be custom-conjugated for flow cytometry panels.

What diagnostic IHC panel do you recommend for melanoma?

A standard melanoma IHC panel includes S100 (high sensitivity), SOX10 (nuclear marker), Melan-A/MART-1 (cytoplasmic), and HMB45/gp100 (specific for melanosomes). We offer antibodies for all four markers.

Do you have tebentafusp-related reagents?

Yes — we offer a research-grade tebentafusp biosimilar and anti-gp100/HLA-A2 complex antibodies for binding characterization, competitive assays, and T-cell redirection studies.

Can I get custom antibodies for novel melanoma neoantigens?

Yes — our parent company AtaGenix provides custom antibody development from immunogen design through monoclonal antibody production, including peptide-MHC complex-targeting antibodies for immuno-oncology.